Novartis AG and Merck KGaA are the front-runners in the race to launch the first oral medicine for multiple sclerosis, with both planning to seek regulatory approval this year for their drugs. Not far behind are Teva Pharmaceutical Industries, Biogen Idec and Sanofi-Aventis, which are expected to release their versions no earlier than 2012.

Full Story:

Related Summaries